Article Per Year (5 Year)
p-Index From 2021 - 2026
3.092
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences Journal of Food and Pharmaceutical Science Journal of Mathematical and Fundamental Sciences Indonesian Journal of Pharmaceutical Science and Technology Indonesian Journal of Biotechnology Science and Technology Indonesia Jurnal Pemberdayaan Masyarakat Madani (JPMM) Molecular and Cellular Biomedical Sciences (MCBS) Resona : Jurnal Ilmiah Pengabdian Masyarakat Dinamisia: Jurnal Pengabdian Kepada Masyarakat Journal of Islamic Medicine JPSCR : Journal of Pharmaceutical Science and Clinical Research Jurnal Abdimas Ilmiah Citra Bakti (JAICB) MAHESA : Malahayati Health Student Journal Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Pharmaceutical Sciences and Research (PSR) Journal Community Service Consortium Jurnal Farmasi Indonesia Journal of Food and Pharmaceutical Sciences
Marisca Evalina Gondokesumo, Marisca Evalina
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Arts Humanities Astronomy Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Computer Science & IT Dentistry Earth & Planetary Sciences Economics, Econometrics & Finance Education Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Materials Science & Nanotechnology Mathematics Medicine & Pharmacology Neuroscience Nursing Physics Public Health Social Sciences Other

Published : 23 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 23 Documents
Search

 1   2   3 
Mangosteen Peel Extract (Garcinia mangostana L.) as a Potential Complementary of Leukemia Therapy: In Vitro and In Silico Studies Gondokesumo, Marisca Evalina; Novilla, Arina; Prahastuti, Sijani; Zahiroh, Fadhilah Haifa; Kusuma, Hanna Sari Widya; Widowati, Wahyu; Azis, Rizal; Hadiprasetyo, Dhanar Septyawan; Nurjamil, Aris Muhammad; Surakusumah, Wahyu; Adha, Khoerotul Nur Fadhilah
Journal of Mathematical and Fundamental Sciences Vol. 57 No. 2 (2025)
Publisher : Directorate for Research and Community Services (LPPM) ITB

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.5614/j.math.fund.sci.2025.57.2.3

Abstract

Leukemia is caused by abnormal white blood cell proliferation that leads to disruption of conventional blood cell functions. Mangosteen (Garcinia mangostana L.) contains phytochemical compounds with strong anticancer properties, according to various cancer studies. This study investigated the potential of mangosteen peel extract (MPE) as an anti-leukemia agent through molecular docking of LC-MS-identified compounds against FLT-1 and AKT proteins, followed by in vitro evaluation on HL-60 cells, namely cytotoxic (WST-8 assay), ROS levels and senescence (flow cytometry), and then FLT1 and AKT gene expression (qRT-PCR). LC-MS identified α-mangostin, β-mangostin, γ-mangostin, mangostinone, and epicatechin as the main compounds. Molecular docking revealed strong binding affinities from −8.5 to −9.9 kcal/mol against AKT, and from −9.0 to −9.9 kcal/mol against FLT-1. MPE (500 µg/mL) decreased cell viability and increased inhibition of HL-60 cells. Intracellular ROS levels decreased significantly at 0.6, 1.2, and 2.4 µg/mL MPE. MPE induced cell senescence especially at 1.2 and 2.4 µg/mL. Gene expression analysis revealed downregulation of AKT at 1.2 and 2.4 µg/mL and FLT1 at 2.4 µg/mL. These findings suggest that MPE may exert multifactorial anti-leukemic mechanisms, including apoptosis, ROS modulation, senescence induction, and regulation of AKT and FLT1 expression.
ANALISIS COST EFFECTIVENESS METHOTREXATE VS LEFLUNOMIDE PADA TERAPI RHEUMATOID ARTHRITIS: NARRATIVE REVIEW DAN IMPLIKASI DI INDONESIA Mardia, Sita Rizky; Gondokesumo, Marisca Evalina; Pratama, Jainuri Erik
Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 11 No 1 (2026): Jurnal Ilmiah Ibnu Sina
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jiis.v11i1.2658

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with substantial clinical and economic burden. Methotrexate (MTX) is recommended as first-line therapy, whereas leflunomide (LEF) is used as an alternative or adjunctive treatment in specific clinical circumstances. This review aims to analyze the comparison between LEF and MTX from the perspectives of clinical efficacy, health economic assumptions, and their relevance within Indonesia’s National Health Insurance system (Jaminan Kesehatan Nasional, JKN). A narrative review methodology was employed, synthesizing international and national clinical and pharmacoeconomic studies published between 1999 and 2024. The findings indicate that the clinical effectiveness of LEF and MTX is generally comparable; however, most economic models developed in high-income countries rely on cost structures, utility values, and willingness-to-pay (WTP) thresholds that limit their transferability to the Indonesian context. Within the JKN framework, which emphasizes cost containment and budget efficiency, MTX remains the most cost-effective first-line therapy due to its low generic price and adequate clinical effectiveness. LEF retains a role as an alternative or sequential therapy and may be considered an intermediate strategy prior to escalation to substantially more expensive biologic agents. Significant local evidence gaps persist, particularly regarding long-term economic models based on national data, incremental cost-effectiveness ratio (ICER) analyses, and budget impact evaluations within the BPJS system. The development of pharmacoeconomic models grounded in the national payer perspective is therefore essential to support more context-specific and sustainable policy decision-making.
Adjusment Dosis pada Pengobatan Tuberculosis Paru Terkonfirmasi Bakteriologis dengan Gangguan Fungsi Ginjal: Case Report Study Tanayawati, Tri; Yulia, Rika; Herawati, Fauna; Erik, Januari; Fatmawati, Umi; Gondokesumo, Marisca Evalina
JPSCR: Journal of Pharmaceutical Science and Clinical Research Vol 11, No 1 (2026)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/jpscr.v11i1.87600

Abstract

Pengobatan Tuberculosis (TB) secara signifikan mempengaruhi fungsi ginjal karena banyak obat TB diekskresikan melalui ginjal. Akibatnya, pada pasien dengan chronic kidney disease (CKD), dosis pemberian yang tidak tepat akan berujung pada kegagalan terapi atau meningkatnya efek samping. Laporan kasus ini bertujuan untuk mengevaluasi dampak penyesuaian dosis obat antituberkulosis (OAT), berbasis fungsi ginjal terhadap keamanan dan luaran klinis pada pasien TB dengan CKD stadium lanjut.  Seorang pasien sesak nafas selama 3 bulan terdiagnosis sebagai Tuberculosis (TB) paru terkonfirmasi bakteriologis yang sedang terapi antituberkulosis (OAT), Acute Kidney Injury (AKI) dd Acute on Chronic Kidney Disease (ACKD) mendapatkan terapi obat antituberkulosis (OAT) yang sudah dilakukan penyesuaian dosis berdasarkan nilai klirens kreatinin yaitu rifampisin 600 mg dan isoniazid 300 mg diberikan masing-masing tiap 24 jam. Pirazinamid 1250 mg dan etambutol 1000 mg diberikan 3x seminggu (senin, rabu, jumat. Hasil ini menunjukkan bahwa penyesuaian dosis berdasarkan fungsi ginjal untuk pasien CKD menghasilkan hasil yang baik dalam 11.0 mg/dL turun menjadi 8.3 mg/dL hal kemanjuran terapi yang serupa dengan pasien non-CKD. Penyesuaian dosis OAT berbasis fungsi ginjal meningkatkan keamanan terapi tanpa mengurangi efektivitas pengobatan. Pemantauan fungsi ginjal secara berkala direkomendasikan untuk mengoptimalkan luaran klinis dan mencegah toksisitas obat pada pasien tuberkulosis dengan CKD.
Co-Authors Abdul Aziz Adha, Khoerotul Nur Fadhilah Anggraeni, Reta Anita Purnamayanti Ardiansyahmiraja, Bobby Auliyana, Iftitah Putri Azis, Rizal Azminah Azminah Azminah Badriah, Rani Nur Budipramana, Krisyanti Djayapranata, Grace Felicia Elisabeth, Mariska Erik, Januari Faisal Akhmal Muslikh Girsang, Ermi Gunanegara, Rimonta Febby Hadiprasetyo, Dhanar Septyawan Hanna Sari Widya Kusuma, Hanna Sari Widya Harjanti, Mathelda Weni Haryanti, Mathelda Weni Hayati, Syafira Nur Herawati, Fauna Ma'arif, Burhan Mardia, Sita Rizky Mariana Wahjudi, Mariana Mars, Nicholas Muthmainnah, Anis Syabani Nindya, Faradhina Salfa Novilla, Arina Nurjamil, Aris Muhammad Pratama, Jainuri Erik Putri, Rizky Ayu Artama RAHMAT, DENI Retno Wilujeng Susilowati, Retno Wilujeng Rika Yulia Rizki Rahmadi Pratama Saksono, Astrella Amanda Putri Saufa, Zahra Qisthi Setiadi, Adji Prayitno Setiadi, Antonius Adji Prayitno Sijani Prahastuti Simanjuntak, Inana Ratu Soripada Suryaningsih, Dwie Retna Suryaningsih, Retna Sutejo, Erwin Takasenserang, Oktaviana Tanayawati, Tri Teresa Liliana Wargasetia Triharsiwi, Dwi Nur UMI FATMAWATI Wahyu Surakusumah WAHYU WIDOWATI Wibowo, Yosi Irawati Widya, Reta Anggraeni Zahiroh, Fadhilah Haifa